Frazier Life Sciences Management, L.P.

PALO ALTO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$4.03B2026 Q3
Positions44
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.70.8%

Frazier Life Sciences Management, L.P. reported 44 positions worth $4.03B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: MIRM (16.3%). Biggest move: new buy ATTO ($120.8M).

10 / 44 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 MIRMMirum Pharmaceuticals$656.5M16.29%7,679,684——+7.1%
▸ 2 NAMSNewAmsterdam Pharma Co$461.8M11.46%18,988,902——-20.0%
▸ 3 ERASErasca$432.1M10.72%29,475,188———
▸ 4 MBXMBX Biosciences$389.9M9.67%6,652,013——-9.4%
▸ 5 ARQTArcutis Biotherapeutics$261.0M6.48%9,874,511——+2.7%
▸ 6 MAZEMaze Therapeutics$143.6M3.56%5,282,915——+24.7%
▸ 7 TRVITrevi Therapeutics$136.6M3.39%9,539,147——-7.2%
▸ 8 KRYSKrystal Biotech$130.1M3.23%391,319——-10.4%
▸ 9 PVLAPalvella Therapeutics$121.7M3.02%882,400——+4.8%
▸ 10 ATTOAttovia Therapeutics$120.8M3.00%7,046,271——-11.7%

Pro Feature

The remaining 34 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Frazier Life Sciences Management, L.P. hold as of Q3 2026?

Frazier Life Sciences Management, L.P. reported 44 positions worth $4.03B in its Q3 2026 13F filing. Largest positions: MIRM (16.3%), NAMS (11.5%), ERAS (10.7%), MBX (9.7%) and ARQT (6.5%).

What did Frazier Life Sciences Management, L.P. buy in Q3 2026?

New positions: ATTO, BRVE, ASND, CLDX and SRPT (7 in all). Added to: ERAS, MNKD, NAMS, ACRS and PBLS (10 in all).

What did Frazier Life Sciences Management, L.P. sell in Q3 2026?

Reduced: SVRA, KRYS, IRON, TRVI and TARS. Sold out entirely: BBIO, CYTK, ASCENDIS PHARMA A/S and ALKS.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.